{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:26:55Z","timestamp":1783571215966,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-023-09593-1","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T12:04:27Z","timestamp":1680782667000},"page":"6438-6447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Hybrid simultaneous whole-body 2-[18F]FDG-PET\/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9182","authenticated-orcid":false,"given":"Bastien","family":"Jamet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bodet-Milin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Frampas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Kraeber-Bodere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"9593_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548","journal-title":"Lancet Oncol"},{"issue":"6","key":"9593_CR2","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV et al (2019) International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20(6):e302\u2013e312","journal-title":"Lancet Oncol"},{"issue":"9","key":"9593_CR3","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","volume":"28","author":"J Hillengass","year":"2010","unstructured":"Hillengass J, Fechtner K, Weber M-A et al (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28(9):1606\u201310","journal-title":"J Clin Oncol"},{"issue":"12","key":"9593_CR4","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/leu.2014.230","volume":"28","author":"E Kastritis","year":"2014","unstructured":"Kastritis E, Moulopoulos LA, Terpos E, Koutoulidis V, Dimopoulos MA (2014) The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia 28(12):2402\u20132403","journal-title":"Leukemia"},{"issue":"2","key":"9593_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/leu.2015.291","volume":"30","author":"E Zamagni","year":"2016","unstructured":"Zamagni E, Nanni C, Gay F et al (2016) 18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 30(2):417\u2013422","journal-title":"Leukemia"},{"key":"9593_CR6","doi-asserted-by":"crossref","unstructured":"Moreau P, Attal M, Caillot D et al (2017) Prospective evaluation of magnetic resonance imaging and [18F] fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study.\u00a0J Clin Oncol\u00a035(25):2911\u20132918","DOI":"10.1200\/JCO.2017.72.2975"},{"issue":"23","key":"9593_CR7","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C et al (2011) Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118(23):5989\u20135995","journal-title":"Blood"},{"issue":"10","key":"9593_CR8","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TLY et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114(10):2068\u20132076","journal-title":"Blood"},{"issue":"6","key":"9593_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Ikeda S, Kitadate A et al (2019) Low hexokinase-2 expression-associated false-negative (18) F-FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging 46(6):1345\u20131350","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"9593_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00259-020-05049-6","volume":"48","author":"B Jamet","year":"2021","unstructured":"Jamet B, Morvan L, Nanni C et al (2021) Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging 48(4):1005\u20131015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"9593_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1186\/s12885-019-6080-8","volume":"19","author":"L Benaniba","year":"2019","unstructured":"Benaniba L, Tessoulin B, Trudel S et al (2019) The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. BMC Cancer 19(1):855","journal-title":"BMC Cancer"},{"issue":"1","key":"9593_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1148\/radiol.2019181949","volume":"291","author":"C Messiou","year":"2019","unstructured":"Messiou C, Hillengass J, Delorme S et al (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology 291(1):5\u201313","journal-title":"Radiology"},{"issue":"9","key":"9593_CR13","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.ejrad.2013.04.012","volume":"82","author":"J Dutoit","year":"2013","unstructured":"Dutoit J, Vanderkerken M, Verstraete KL (2013) Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma. Eur J Radiol 82(9):1444\u20131452","journal-title":"Eur J Radiol"},{"issue":"3","key":"9593_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","volume":"43","author":"C Nanni","year":"2016","unstructured":"Nanni C, Zamagni E, Versari A et al (2016) Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 43(3):414\u2013421","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"9593_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00330-011-2116-4","volume":"21","author":"C Messiou","year":"2011","unstructured":"Messiou C, Collins DJ, Morgan VA, Desouza NM (2011) Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol 21(8):1713\u20131718","journal-title":"Eur Radiol"},{"key":"9593_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21\u201333","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"9593_CR17","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1007\/s00259-020-05182-2","volume":"48","author":"O Westerland","year":"2021","unstructured":"Westerland O, Amlani A, Kelly-Morland C et al (2021) Comparison of the diagnostic performance and impact on management of 18F-FDG PET\/CT and whole-body MRI in multiple myeloma. Eur J Nucl Med Mol Imaging 48(8):2558\u20132565","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9593_CR18","doi-asserted-by":"crossref","unstructured":"Burns R, Mul\u00e9 S, Blanc-Durand P et al (2021) Optimization of whole-body 2-[18F]FDG-PET\/MRI imaging protocol for the initial staging of patients with myeloma. Eur Radiol. 32(5):3085\u20133096","DOI":"10.1007\/s00330-021-08388-6"},{"issue":"1","key":"9593_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE et al (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130(1):304","journal-title":"Blood"},{"issue":"12","key":"9593_CR20","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/ajh.25279","volume":"93","author":"MA Aljama","year":"2018","unstructured":"Aljama MA, Sidiqi MH, Buadi FK et al (2018) Utility and prognostic value of 18F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. Am J Hematol 93(12):1518\u20131523","journal-title":"Am J Hematol"},{"issue":"1","key":"9593_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00259-018-4114-0","volume":"46","author":"S-H Jung","year":"2019","unstructured":"Jung S-H, Kwon SY, Min J-J et al (2019) 18F-FDG PET\/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the revised international staging system. Eur J Nucl Med Mol Imaging 46(1):107\u2013115","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"9593_CR22","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3390\/cancers12092532","volume":"12","author":"AV Michaud-Robert","year":"2020","unstructured":"Michaud-Robert AV, Zamagni E, Carlier T et al (2020) Glucose metabolism quantified by SUVmax on baseline FDG-PET\/CT predicts survival in newly diagnosed multiple myeloma patients: combined harmonized analysis of two prospective phase III trials. Cancers (Basel) 12(9):2532","journal-title":"Cancers (Basel)"},{"key":"9593_CR23","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C et al (2017) International Myeloma Working Group. Review Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 18:e206-2017","journal-title":"Lancet Oncol"},{"key":"9593_CR24","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/leu.2010.70","volume":"24","author":"LA Moulopoulos","year":"2010","unstructured":"Moulopoulos LA, Dimopoulos MA, Christoulas D et al (2010) Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia 24:1206\u20131212","journal-title":"Leukemia"},{"issue":"5","key":"9593_CR25","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00259-020-05078-1","volume":"48","author":"A Paschali","year":"2021","unstructured":"Paschali A, Panagiotidis E, Triantafyllou T et al (2021) A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy. Eur J Nucl Med Mol Imaging 48(5):1487\u20131497","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-023-09593-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-023-09593-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-023-09593-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T15:11:12Z","timestamp":1691680272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-023-09593-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["9593"],"URL":"https:\/\/doi.org\/10.1007\/s00330-023-09593-1","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]},"assertion":[{"value":"7 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Francoise Kraeber-Bodere (FKB), head of Nantes University Hospital\u2019s department of nuclear medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional review board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Some study subjects or cohorts have previously been reported in Benaniba L, Tessoulin B, Trudel S, et al The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. <i>BMC Cancer<\/i>. 2019;19(1):855.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cohort overlap"}},{"value":"\u2022 prospective\u2022 diagnostic study\u2022 performed at one institution","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}